Entrada Therapeutics (NASDAQ:TRDA) Issues Quarterly Earnings Results, Beats Expectations By $0.04 EPS

Entrada Therapeutics (NASDAQ:TRDA) issued its earnings results on Thursday. The company reported ($0.94) earnings per share for the quarter, beating the consensus estimate of ($0.98) by $0.04, FiscalAI reports. Entrada Therapeutics had a negative net margin of 3,537.73% and a negative return on equity of 57.61%. The firm had revenue of $0.91 million for the quarter, compared to analysts’ expectations of $2.30 million.

Entrada Therapeutics Trading Up 2.5%

Shares of NASDAQ TRDA traded up $0.12 during mid-day trading on Friday, reaching $4.67. The company had a trading volume of 16,478 shares, compared to its average volume of 334,979. The firm has a 50 day simple moving average of $5.84 and a two-hundred day simple moving average of $8.61. The stock has a market cap of $181.64 million, a P/E ratio of -1.18 and a beta of -0.19. Entrada Therapeutics has a 52-week low of $4.11 and a 52-week high of $16.45.

Insider Buying and Selling at Entrada Therapeutics

In other Entrada Therapeutics news, major shareholder Bioventures 2014 L.P. Mpm sold 14,569 shares of the firm’s stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $7.06, for a total transaction of $102,857.14. Following the transaction, the insider owned 4,318,348 shares of the company’s stock, valued at approximately $30,487,536.88. This trade represents a 0.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, major shareholder Bioventures 2018 L.P. Mpm sold 28,837 shares of the firm’s stock in a transaction dated Wednesday, September 9th. The stock was sold at an average price of $7.13, for a total value of $205,607.81. Following the transaction, the insider directly owned 3,885,115 shares in the company, valued at approximately $27,700,869.95. The trade was a 0.74% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 588,391 shares of company stock worth $4,247,578 over the last quarter. 9.49% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on TRDA shares. UBS Group reissued a “neutral” rating on shares of Entrada Therapeutics in a research report on Monday, October 19th. Wall Street Zen cut shares of Entrada Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, November 1st. HC Wainwright reiterated a “neutral” rating on shares of Entrada Therapeutics in a research note on Monday, October 19th. Weiss Ratings raised Entrada Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday. Finally, Roth Capital reissued a “buy” rating and issued a $11.00 target price on shares of Entrada Therapeutics in a report on Wednesday, August 12th. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $17.75.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc (NASDAQ:TRDA) is a biotechnology company focused on developing therapeutics designed to enter cells and address diseases caused by abnormal or missing intracellular proteins. The company’s approach is based on its Endosomal Escape Vehicle (EEV) platform, which is intended to deliver therapeutic payloads into target cells while helping them escape the endosome, a cellular compartment that can limit the effectiveness of some treatments.

Entrada is developing EEV-based medicines for serious diseases, particularly genetic and neuromuscular conditions.